A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

Interest exists in the development of antiretroviral agents that possess different mechanisms of action from nucleoside analogs such as AZT. U-87201E is a non-nucleoside reverse transcriptase (RT) inhibitor that has demonstrated activity against HIV-1; however, an emerging characteristic of non-nucleoside RT inhibitors is the development of rapid resistance to HIV isolates. Whether this resistance can be prevented in the presence of nucleoside analogs such as AZT and ddI has yet to be determined.

Part I: Five male patients enter a pharmacokinetic concentration-controlled trial of U-87201E ...

Gender

MALE

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • PCP prophylaxis with aerosolized pentamidine, trimethoprim / sulfamethoxazole or dapsone.
• • Clotrimazole troches or nystatin oral suspension for oral candidiasis.
• • Acyclovir (up to 1000 mg/day) for herpes lesions.
• Patients must have:
• • HIV infection documented by serologic tests or HIV culture OR prior diagnosis of AIDS by established CDC criteria.
• • CD4 counts = or \< 500 cells/mm3 on two evaluations.
• Part II only:
• • No prior therapy with antiretroviral or immunomodulating agents (e.g., AZT, ddI, ddC, interferon).
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following symptoms and conditions are excluded:
• • Acute medical problems at time of study entry (including active opportunistic infections such as active cryptococcosis, Pneumocystis carinii, herpes zoster, histoplasmosis, or CMV, or nonopportunistic diseases including liver disease, renal disease, orthostatic hypotension, hypertension, lymphoma).
• • Current diagnosis of malignancy for which systemic therapy would be required during the study.
• Concurrent Medication:
• Excluded:
• • Any other investigational drugs.
• • Phenobarbital, phenytoin, ketoconazole, rifampin, cimetidine, beta blockers, chronic anti-acid therapy, antiarrhythmic agents or other medications known to affect cardiac conduction or seizure threshold.
• • Cytotoxic chemotherapy.
• Patients with the following prior conditions are excluded:
• • History of cardiovascular disease including conduction disturbances, arrhythmias, atherosclerotic heart disease, or valvular heart disease.
• • History of CNS disease such as seizure disorder, AIDS Dementia Complex, Progressive Multifocal Leukoencephalopathy, or any other active neurological disorder.
• • History of active or chronic gastrointestinal disorders such as chronic diarrhea (\> 4 weeks duration), constipation, unexplained abdominal pain (such as irritable bowel syndrome), or other GI motility disorders.
• • History of hypercholesterolemia requiring medication or serum cholesterol = or \> 300.
• Part I patients only:
• • History of inability to tolerate zidovudine (200 mg q 8 hours).
• Part III patients only:
• • History of pancreatitis or \> grade 2 peripheral neuropathy.
• Prior Medication:
• Excluded:
• • Cytotoxic chemotherapy within 1 month prior to study entry.
• Part II only:
• • prior therapy with antiretroviral or immunomodulatory agents (including but not limited to AZT, ddI, ddC, and interferon).
• • Current use of alcohol or illicit drugs.

Trial Officials